{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:11:53Z","timestamp":1783631513315,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI234916"],"award-info":[{"award-number":["WI234916"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijid.2026.108691","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:16:32Z","timestamp":1775517392000},"page":"108691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Risk factors for mortality and severe functional decline in adults with invasive pneumococcal disease: A prospective multicenter cohort study"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4869-5548","authenticated-orcid":false,"given":"Takaya","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108691_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00740-0","article-title":"Future immunisation strategies to prevent Streptococcus pneumoniae infections in children and adults","author":"Ramos","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108691_bib0002","unstructured":"Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease (IPD) (2010 case definition). National Notifiable Diseases Surveillance System (NNDSS). 2010 [accessed 23 January 2026], https:\/\/ndc.services.cdc.gov\/case-definitions\/invasive-pneumococcal-disease-2010\/."},{"key":"10.1016\/j.ijid.2026.108691_bib0003","article-title":"Prognostic factors for mortality in invasive pneumococcal disease in adults: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ijid.2026.108691_bib0004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1086\/518538","article-title":"Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study","volume":"45","author":"Alanee","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108691_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039150","article-title":"Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into nonvaccine serotypes","volume":"7","author":"van Hoek","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijid.2026.108691_bib0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1183\/09031936.00050413","article-title":"Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes","volume":"43","author":"Burgos","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ijid.2026.108691_bib0007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/655828","article-title":"Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis","volume":"51","author":"Weinberger","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"9920","key":"10.1016\/j.ijid.2026.108691_bib0008","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(13)60688-1","article-title":"Delirium in elderly people","volume":"383","author":"Inouye","year":"2014","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ijid.2026.108691_bib0009","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1001\/jama.2010.1553","article-title":"Long-term cognitive impairment and functional disability among survivors of severe sepsis","volume":"304","author":"Iwashyna","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijid.2026.108691_bib0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Garcia Quesada","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108691_bib0011","series-title":"25th Informational Supplement M100-S25","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.ijid.2026.108691_bib0012","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijid.2026.108691_bib0013","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.resinv.2025.06.014","article-title":"Japanese Respiratory Society systematic review team for the Japanese Clinical Practice Guidelines for Pneumonia in adults 2024. The JRS guideline for the management of pneumonia in adults 2024","volume":"63","author":"Mukae","year":"2025","journal-title":"Respir Investig"},{"issue":"7","key":"10.1016\/j.ijid.2026.108691_bib0014","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2026.108691_bib0015","series-title":"17th Informational Supplement M100-S17","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2007"},{"issue":"5","key":"10.1016\/j.ijid.2026.108691_bib0016","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens12050732","article-title":"A systematic review and meta-analysis of pneumococcal polysaccharide vaccine effectiveness in adults","volume":"12","author":"Berild","year":"2023","journal-title":"Pathogens"},{"issue":"8","key":"10.1016\/j.ijid.2026.108691_bib0017","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.108691_bib0018","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/thx.2009.123612","article-title":"Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes","volume":"65","author":"Garcia-Vidal","year":"2010","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.ijid.2026.108691_bib0019","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/thoraxjnl-2012-203106","article-title":"Henriques Normark B. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia","volume":"65","author":"Naucler","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.ijid.2026.108691_bib0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1086\/313716","article-title":"Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia","volume":"30","author":"Metlay","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108691_bib0021","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jmii.2023.01.013","article-title":"Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: a multicenter observational study","volume":"56","author":"Aydin","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijid.2026.108691_bib0022","article-title":"Evolution of invasive pneumococcal disease by serotype 3 in adults following paediatric PCV13 introduction","volume":"41","author":"Carratal\u00e0","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ijid.2026.108691_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.613287","article-title":"Sugar-coated killer: serotype 3 pneumococcal disease","volume":"10","author":"Luck","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"10.1016\/j.ijid.2026.108691_bib0024","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ijid.2026.108691_bib0025","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","article-title":"Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial","volume":"24","author":"Platt","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108691_bib0026","article-title":"Vaccines for preventing pneumococcal infection in adults","volume":"1","author":"Moberley","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2026.108691_bib0027","doi-asserted-by":"crossref","first-page":"c1004","DOI":"10.1136\/bmj.c1004","article-title":"Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing pneumonia and death in elderly people: a randomised, double-blind, placebo-controlled trial","volume":"340","author":"Maruyama","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ijid.2026.108691_bib0028","doi-asserted-by":"crossref","first-page":"e5687","DOI":"10.1002\/gps.5687","article-title":"Hospital-associated deconditioning: not only physical, but also cognitive","volume":"37","author":"Chen","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.ijid.2026.108691_bib0029","doi-asserted-by":"crossref","first-page":"151","DOI":"10.14336\/AD.2017.0315","article-title":"Acute sarcopenia secondary to hospitalisation\u2014an emerging condition affecting older adults","volume":"9","author":"Welch","year":"2018","journal-title":"Aging Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226003267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226003267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:20:05Z","timestamp":1781461205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226003267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"alternative-id":["S1201971226003267"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108691","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for mortality and severe functional decline in adults with invasive pneumococcal disease: A prospective multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108691"}}